| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A novel way to manage trastuzumab cardiotoxicity
|
Hamdan, Diaddin
|
|
2018
|
81 |
4 |
p. 791-796
|
artikel
|
| 2 |
Combination of S-1 and gefitinib increases the sensitivity to radiotherapy in lung cancer cells
|
Cui, Jie
|
|
2018
|
81 |
4 |
p. 717-726
|
artikel
|
| 3 |
Electrophilic derivatives of omega-3 fatty acids counteract lung cancer cell growth
|
Siena, Liboria
|
|
2018
|
81 |
4 |
p. 705-716
|
artikel
|
| 4 |
Evaluation of hepatic impairment on pharmacokinetics and safety of crizotinib in patients with advanced cancer
|
El-Khoueiry, Anthony B.
|
|
2018
|
81 |
4 |
p. 659-670
|
artikel
|
| 5 |
FDG PET/CT after first molecular targeted therapy predicts survival of patients with renal cell carcinoma
|
Nakaigawa, Noboru
|
|
2018
|
81 |
4 |
p. 739-744
|
artikel
|
| 6 |
Ibrutinib brain distribution: a preclinical study
|
Goldwirt, Lauriane
|
|
2018
|
81 |
4 |
p. 783-789
|
artikel
|
| 7 |
Incidence of leukopenia and thrombocytopenia with cisplatin plus mitomycin-c versus melphalan in patients undergoing cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC)
|
Hakeam, Hakeam A.
|
|
2018
|
81 |
4 |
p. 697-704
|
artikel
|
| 8 |
Influence of gemcitabine chemotherapy on the microbiota of pancreatic cancer xenografted mice
|
Panebianco, Concetta
|
|
2018
|
81 |
4 |
p. 773-782
|
artikel
|
| 9 |
Long non-coding RNA TUSC7 inhibits temozolomide resistance by targeting miR-10a in glioblastoma
|
Shang, Chao
|
|
2018
|
81 |
4 |
p. 671-678
|
artikel
|
| 10 |
Monitoring of erlotinib in pancreatic cancer patients during long-time administration and comparison to a physiologically based pharmacokinetic model
|
Gruber, Andrea
|
|
2018
|
81 |
4 |
p. 763-771
|
artikel
|
| 11 |
PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer
|
Morgan, Robert D.
|
|
2018
|
81 |
4 |
p. 647-658
|
artikel
|
| 12 |
Phase 1, open-label, dose-escalation study of sorafenib in combination with eribulin in patients with advanced, metastatic, or refractory solid tumors
|
Marmé, Frederik
|
|
|
81 |
4 |
p. 727-737
|
artikel
|
| 13 |
Phase 1, open-label, dose-escalation study of sorafenib in combination with eribulin in patients with advanced, metastatic, or refractory solid tumors
|
Marmé, Frederik
|
|
2018
|
81 |
4 |
p. 727-737
|
artikel
|
| 14 |
Phosphorylation of AKT and ERK1/2 and mutations of PIK3CA and PTEN are predictive of breast cancer cell sensitivity to everolimus in vitro
|
Citi, Valentina
|
|
2018
|
81 |
4 |
p. 745-754
|
artikel
|
| 15 |
Randomized phase II study of anastrozole plus tegafur-uracil as neoadjuvant therapy for ER-positive breast cancer in postmenopausal Japanese women (Neo-ACET BC)
|
Nakayama, Takahiro
|
|
2018
|
81 |
4 |
p. 755-762
|
artikel
|
| 16 |
Role of immunotherapy in bladder cancer: past, present and future
|
Butt, Sabeeh-ur-Rehman
|
|
2018
|
81 |
4 |
p. 629-645
|
artikel
|
| 17 |
Role of immunotherapy in bladder cancer: past, present and future
|
Butt, Sabeeh-ur-Rehman
|
|
|
81 |
4 |
p. 629-645
|
artikel
|
| 18 |
Safety profile of nivolumab administered as 30-min infusion: analysis of data from CheckMate 153
|
Waterhouse, David
|
|
2018
|
81 |
4 |
p. 679-686
|
artikel
|
| 19 |
YSA-conjugated mesoporous silica nanoparticles effectively target EphA2-overexpressing breast cancer cells
|
Liu, Zhi
|
|
2018
|
81 |
4 |
p. 687-695
|
artikel
|
Tijdschrift beschrijving